NEW YORK (GenomeWeb) – South Korean genomic services provider Macrogen announced today that it has acquired a non-exclusive research tool license to CRISPR-Cas9 technology from the Broad Institute.

Macrogen said that it intends to use the genome-editing technology to build preclinical animal models and for target treatment function analysis to advance precision medicine and gene therapy research and development.

Specific terms of the deal were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

US News & World Report writes that genetic testing of lung tumors can help identify treatments for patients.

A team of researchers plans to sample Loch Ness for environmental DNA, according to Newsweek.

The New York Times writes about the appearance of mosaicism in healthy people.

In PNAS this week: insecticide resistance patterns Anopheles gambiae mosquito, transcriptome patterns in Pseudomonas aeruginosa during infection, and more.